共 50 条
Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET
被引:41
|作者:
Paudyal, Pramila
[1
,2
]
Paudyal, Bishnuhari
[1
,2
]
Hanaoka, Hirofumi
Oriuchi, Noboru
[1
,2
]
Iida, Yashuhiko
Yoshioka, Hiroki
[1
,2
]
Tominaga, Hideyuki
[1
,2
]
Watanabe, Satoshi
[3
]
Watanabe, Shigeki
[3
]
Ishioka, Noriko S.
[3
]
Endo, Keigo
[1
,2
]
机构:
[1] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol, Maebashi, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Dept Nucl Med, Maebashi, Gunma, Japan
[3] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Takasaki, Gunma, Japan
关键词:
PHASE-II TRIAL;
BREAST-CANCER;
ANTIBODY;
GEMCITABINE;
CISPLATIN;
MICE;
D O I:
10.1111/j.1349-7006.2010.01480.x
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of 64 Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Trastuzumab was conjugated with the bifunctional chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) and radiolabeled with Cu-64. The molecular specificity of DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu overexpression (NCI-H2170) and negative expression (NCI-H520). Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with 64 Cu-DOTA-trastuzumab PET and 64 Cu-DOTA-IgG. In vitro studies revealed specific binding of DOTA-trastuzumab in the Her2/neu positive NCI-H2170 cells, while no binding was seen in the Her2/neu negative NCI-H520 cell line. Biodistribution and PET studies revealed a significantly high accumulation of 64 CuDOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 and 48 h post-injection (21.4 +/- 1.4% and 23.2 +/- 5.1% injection dose/gram (% ID/g), respectively). PET imaging of Her2/neu negative NCI-H520 tumors showed much less uptake of 64 CuDOTA- trastuzumab (4.0% ID/g). The NCI-H2170 tumor uptake of 64 Cu-DOTA-trastuzumab was significantly higher than that of 64 Cu-DOTA-IgG (P < 0.0001). 64 Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy. (Cancer Sci 2010; 101: 1045-1050)
引用
收藏
页码:1045 / 1050
页数:6
相关论文